Martin from France

Registered at the short selling broker Capital, 2 minutes ago.

» Try Capital you too
71.2% of retail investor accounts lose money when trading CFDs with Capital.
Don't show again

Takeda Pharmaceutical Co., Ltd (TAK) shares information

Takeda Pharmaceutical Co – ADR


24h Change

0.53 %

TAK

Live rate: Market closed

Stock data per Monday 10 May, 2021

TAK
NEW YORK STOCK EXCHANGE, INC.
16.87
17.09
16.96
0.09 (+ 0.53%)
US Market is closed

Live Stock price in graph for Takeda Pharmaceutical Co – ADR (TAK)

  • Latest Volume

    3,210,628 (32.78 %)

  • Volume prev. day

    2,418,011

  • Avg. daily volume

    2,171,030

  • Market cap

    53,520,676,070

  • P/E ratio

    n/a

  • Today high

    17.14 USD

  • Today low

    16.93 USD

  • 52 week high

    19.97 USD

  • 52 week low

    15.3 USD

  • YTD Change

    n/a

Quick links

 

Latest news about Takeda Pharmaceutical Co – ADR

Below you can find the most recent news posts about Takeda Pharmaceutical Co – ADR, primarily from US and UK based news sources.

Anima attracts Takeda in potential multibillion-dollar deal

Tuesday, 23 March 2021, 19:22:00
Small-molecule mRNA translation expert Anima Biotech Inc. has landed a significant new preclinical research deal with Takeda Pharmaceutical Co. Ltd., covering as many as six programs for genetically defined neurological diseases. The deal starts with $120 million in up-front and preclinical research milestone payments for Anima, but altogether the two-part collaboration could hold as much as $2.3 billion in clinical and commercial milestone payouts for the company, providing substantial support for its internal pipeline, Anima co-founder and CEO Yochi Slonim told BioWorld .
— BioWorld


MENA Biologics & Biosimilars Market Major Players Analysis Hoffmann-la Roche Ag, Regeneron Pharmaceuticals, Inc., Pfizer, Inc., Amgen, Inc., Sanofi S.A., and Takeda Pharmaceutical Company Limited

Thursday, 18 March 2021, 13:41:57
MENA Biologics & Biosimilars Market report is an in-depth analysis study offered which explains necessary aspects like competition, segmentation, and regional growth in excessive detail. As a part of competitive analysis, the analysis study includes thorough company identification of leading
— OpenPR


Japan’s Takeda, Germany’s IDT Biologika to make Johnson & Johnson's single-dose Covid-19 vaccine

Monday, 15 March 2021, 19:19:40
BENGALURU/BERLIN: Japan's Takeda Pharmaceutical Co Ltd said on Monday it has signed an agreement with Germany-based contract manufacturer IDT Biologika GmbH to make Johnson & Johnson's single-dose Covid-19 vaccine. J&J's vaccine, authorized in the United States on Feb 27, is the first single-dose coronavirus vaccine alongside two-shot vaccines from Pfizer/BioNTech and Moderna Inc. The latest move will help ease some concerns in Europe about J&J's ability to meet production goals. The drugmaker has been working to expand the manufacturing capacity for its vaccine and previously tapped contract manufacturers such as Catalent and Emergent to scale up production and meet global supply goals. Merck & Co and France's Sanofi agreed to help make J&J's vaccine earlier this year. A European Union official told Reuters earlier this month J&J had flagged possible supply issues that may affect its plans to deliver 55 million vaccine doses to the bloc in the second quarter of the year. Under the contract, the capacity at IDT's Dessau site, previously reserved to make Takeda's dengue vaccine candidate, will be used to make J&J's Covid-19 vaccine for worldwide distribution.
— The Sun Daily


UPDATE 2-Takeda, IDT to make J&J's COVID-19 vaccine

Monday, 15 March 2021, 12:51:31
Japan's Takeda Pharmaceutical Co Ltd said on Monday it has signed an agreement with Germany-based contract manufacturer IDT Biologika GmbH to make Johnson & Johnson's single-dose COVID-19 vaccine.
— Reuters


Takeda and IDT Support Manufacturing of Johnson & Johnson’s COVID-19 Vaccine

Monday, 15 March 2021, 12:30:00
OSAKA, Japan–(BUSINESS WIRE)–Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced a mutual agreement with IDT Biologika GmbH (“IDT”), a contract development and manufacturing organization, to utilize capacity at IDT previously reserved for Takeda’s dengue vaccine candidate (TAK-003) to manufacture the single-shot COVID-19 vaccine developed by the Janssen Pharmaceutical Companies of Johnson & Johnson. At the end of a three-month period, the capacity will be
— Business Wire


Trading broker recommendation

We recommend that you check out Capital.com as they have a very good selection of stocks available for both going short and long.

Rating: 9.57/10
Minimum deposit: €250 by bank
Description: Capital.com offer a large number of stocks for trading. Register an account today and check if they have TAK available or trade one of the many other CFD stocks they have.
Risk warning: 71.2% of retail investor accounts lose money when trading CFDs with Capital.